Olanzapine may increase the risk of death in older adults with psychosis (loss of touch with reality) related to dementia. Olanzapine is not approved for use in this group of people. For more ...
Please provide your email address to receive an email when new articles are posted on . Low-dose olanzapine appeared noninferior to standard dose for controlling chemotherapy-induced nausea and ...
Am J Health Syst Pharm. 2008;65(12):1180-1183. Ultimately, more formalized, high-quality, and clinically applicable studies are necessary to determine the safety of the parenteral combination of ...
Yoga-based supportive care for patients with head and neck cancer undergoing radiotherapy: Results of a three-arm randomized controlled trial. This is an ASCO Meeting Abstract from the 2023 ASCO ...
Olanzapine LAI (TEV-'749) is an investigational once-monthly subcutaneous LAI of the second-generation antipsychotic olanzapine and is not approved by any regulatory authority for any use, and its ...
Researchers from Japan found that a 5 mg dose of olanzapine, taken after chemotherapy, significantly reduces nausea and vomiting in breast cancer patients, while minimizing sedation and cutting costs.
More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1.
TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results